BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
Complejo Hospitalario de Toledo
Toledo, EspañaPublicaciones en colaboración con investigadores/as de Complejo Hospitalario de Toledo (115)
2024
-
Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723
-
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Annals of Hematology
-
T-cell immune profile in blood of systemic mastocytosis: Association with disease features
Allergy: European Journal of Allergy and Clinical Immunology
2023
-
Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 5, pp. 1536-1547
-
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717
-
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1347-1359
-
Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality
The journal of allergy and clinical immunology. In practice, Vol. 11, Núm. 3, pp. 908-919
-
Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: A prospective case series
Gastroenterologia y Hepatologia
-
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
Altered innate immune profile in blood of systemic mastocytosis patients
Clinical and Translational Allergy, Vol. 12, Núm. 6
-
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis
Cancers, Vol. 14, Núm. 10
-
Design and Rationale for a Real-World Prospective, Multicenter Registry of Myocardial Revascularization Failure and Secondary Revascularization: The REVASEC Study
Cardiovascular Revascularization Medicine, Vol. 40, pp. 50-56
-
Early clinical outcomes after transaxillary versus transfemoral TAVI. Data from the Spanish TAVI registry
Revista Espanola de Cardiologia, Vol. 75, Núm. 6, pp. 479-487
-
Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis
Blood, Vol. 139, Núm. 4, pp. 572-583
-
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950
-
Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2039-2051
-
Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
Clinical and Translational Allergy, Vol. 12, Núm. 3
-
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6
-
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024